Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype
Launched by THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · Jul 16, 2024
Trial Information
Current as of August 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding and improving how we diagnose and treat Adolescent Idiopathic Scoliosis (AIS), a condition where the spine curves abnormally, usually in teenagers. Researchers aim to identify specific biological markers related to AIS and develop better risk prediction models. They want to create enhanced diagnosis and treatment methods that combine both Chinese and Western medicine, with the goal of fully implementing these innovations across Zhejiang Province by the end of 2026.
To participate in this study, individuals must be between 10 and 18 years old and have been diagnosed with AIS. They should be willing to sign consent forms and complete follow-up visits and various tests, including X-rays and genetic assessments. However, individuals with certain spine-related conditions or serious medical problems may not be eligible. Participants can expect to contribute to important research that could lead to more effective treatments for AIS in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with AIS;② Sex is not limited, age 10-18 years old; ③ Those who sign the informed consent and can cooperate with follow-up visits; ④ Those who can cooperate with X-ray, chemical test, genetic test and other examination and evaluation for the measurement of relevant indexes.
- Exclusion Criteria:
- • Subjects with spine-related diseases such as Marfan's syndrome;
- • Subjects with previous ankylosing spondylitis, spinal neurofibroma, spinal tuberculosis, spinal trauma and other spine-related diseases;
- • Subjects with combined serious medical diseases and psychiatric patients;
- • Those with ECOG score \> 2, which may have an impact on the study results;
- • Those who are affected by external factors such as economy, individualized differences, etc., so that they cannot complete the study.
About The First Affiliated Hospital Of Zhejiang Chinese Medical University
The First Affiliated Hospital of Zhejiang Chinese Medical University is a leading institution in clinical research and medical education, renowned for its commitment to advancing healthcare through innovative research initiatives. As a prominent teaching hospital, it integrates cutting-edge medical practices with a strong emphasis on patient care and community health. The hospital is dedicated to fostering collaborative clinical trials that aim to improve therapeutic outcomes and enhance the understanding of various medical conditions. Its experienced team of researchers and healthcare professionals is focused on conducting rigorous and ethical studies, contributing significantly to the global medical community and the advancement of evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Jiang Zhong, bachelor
Study Director
The First Affiliated Hospital of Zhejiang Chinese Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported